Zydus moves to buy Assertio in $166.4 million cash deal

Zydus Lifesciences, through subsidiary Zydus Worldwide DMCC, has agreed to acquire Assertio Holdings in an all-cash deal valued at about $166.4 million, or $23.50 per share. Assertio’s board unanimously approved the agreement and said Zydus’ bid was a “superior proposal,” replacing a previously announced merger agreement with Garda Therapeutics. The transaction is structured as a tender offer followed by a second-step merger, and Assertio said no regulatory approvals are expected to be required. (sec.gov)

Why it matters: For veterinary professionals, this is mainly a signal about capital flows and portfolio strategy across health care rather than a direct animal health development. Assertio has been focused primarily on oncology-supportive care, led by Rolvedon, which generated $68.2 million in 2025 net product sales, while Zydus has been building out specialty and U.S.-market capabilities. Zydus also already has an animal health business serving the U.S. and Europe, so the deal adds to the company’s broader North American footprint, even if the acquired assets are human pharma rather than veterinary products. (sec.gov)

What to watch: Watch for the formal tender offer filing, shareholder response, and whether Zydus uses Assertio’s U.S. commercial platform as a base for further specialty expansion later in 2026. (sec.gov)